Logo image of CRDL.CA

CARDIOL THERAPEUTICS INC-A (CRDL.CA) Stock Fundamental Analysis

Canada - TSX:CRDL - CA14161Y2006 - Common Stock

1.4 CAD
-0.04 (-2.78%)
Last: 11/7/2025, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CRDL. CRDL was compared to 31 industry peers in the Pharmaceuticals industry. While CRDL seems to be doing ok healthwise, there are quite some concerns on its profitability. CRDL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRDL has reported negative net income.
CRDL had a negative operating cash flow in the past year.
CRDL had negative earnings in each of the past 5 years.
CRDL had a negative operating cash flow in each of the past 5 years.
CRDL.CA Yearly Net Income VS EBIT VS OCF VS FCFCRDL.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -188.33%, CRDL is not doing good in the industry: 93.55% of the companies in the same industry are doing better.
The Return On Equity of CRDL (-318.00%) is worse than 83.87% of its industry peers.
Industry RankSector Rank
ROA -188.33%
ROE -318%
ROIC N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
CRDL.CA Yearly ROA, ROE, ROICCRDL.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDL.CA Yearly Profit, Operating, Gross MarginsCRDL.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for CRDL has been increased compared to 1 year ago.
The number of shares outstanding for CRDL has been increased compared to 5 years ago.
The debt/assets ratio for CRDL is higher compared to a year ago.
CRDL.CA Yearly Shares OutstandingCRDL.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRDL.CA Yearly Total Debt VS Total AssetsCRDL.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CRDL has an Altman-Z score of -10.67. This is a bad value and indicates that CRDL is not financially healthy and even has some risk of bankruptcy.
CRDL has a worse Altman-Z score (-10.67) than 83.87% of its industry peers.
CRDL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, CRDL belongs to the top of the industry, outperforming 83.87% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -10.67
ROIC/WACCN/A
WACCN/A
CRDL.CA Yearly LT Debt VS Equity VS FCFCRDL.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

CRDL has a Current Ratio of 2.46. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
CRDL's Current ratio of 2.46 is fine compared to the rest of the industry. CRDL outperforms 61.29% of its industry peers.
A Quick Ratio of 2.46 indicates that CRDL has no problem at all paying its short term obligations.
CRDL has a better Quick ratio (2.46) than 93.55% of its industry peers.
Industry RankSector Rank
Current Ratio 2.46
Quick Ratio 2.46
CRDL.CA Yearly Current Assets VS Current LiabilitesCRDL.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CRDL have decreased by -4.44% in the last year.
EPS 1Y (TTM)-4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CRDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.69% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27%
EPS Next 2Y-5.2%
EPS Next 3Y19.5%
EPS Next 5Y27.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRDL.CA Yearly Revenue VS EstimatesCRDL.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
CRDL.CA Yearly EPS VS EstimatesCRDL.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRDL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRDL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDL.CA Price Earnings VS Forward Price EarningsCRDL.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDL.CA Per share dataCRDL.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

CRDL's earnings are expected to grow with 19.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.2%
EPS Next 3Y19.5%

More info and screens

0

5. Dividend

5.1 Amount

CRDL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIOL THERAPEUTICS INC-A

TSX:CRDL (11/7/2025, 7:00:00 PM)

1.4

-0.04 (-2.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-18 2025-11-18
Inst Owners8.31%
Inst Owner ChangeN/A
Ins Owners4.65%
Ins Owner ChangeN/A
Market Cap122.44M
Revenue(TTM)N/A
Net Income(TTM)-37.55M
Analysts82.5
Price Target9.95 (610.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.14%
Min EPS beat(2)18.3%
Max EPS beat(2)29.97%
EPS beat(4)3
Avg EPS beat(4)8.46%
Min EPS beat(4)-47.06%
Max EPS beat(4)32.64%
EPS beat(8)6
Avg EPS beat(8)10.16%
EPS beat(12)10
Avg EPS beat(12)12.62%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)30.77%
EPS NY rev (1m)0%
EPS NY rev (3m)29.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.37
P/tB 10.37
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -188.33%
ROE -318%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.46
Quick Ratio 2.46
Altman-Z -10.67
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.14%
Cap/Depr(5y)17.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y27%
EPS Next 2Y-5.2%
EPS Next 3Y19.5%
EPS Next 5Y27.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.92%
EBIT Next 3Y13.88%
EBIT Next 5Y25.39%
FCF growth 1Y14.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.92%
OCF growth 3YN/A
OCF growth 5YN/A

CARDIOL THERAPEUTICS INC-A / CRDL.CA FAQ

What is the ChartMill fundamental rating of CARDIOL THERAPEUTICS INC-A (CRDL.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CRDL.CA.


What is the valuation status for CRDL stock?

ChartMill assigns a valuation rating of 0 / 10 to CARDIOL THERAPEUTICS INC-A (CRDL.CA). This can be considered as Overvalued.


Can you provide the profitability details for CARDIOL THERAPEUTICS INC-A?

CARDIOL THERAPEUTICS INC-A (CRDL.CA) has a profitability rating of 0 / 10.


How financially healthy is CARDIOL THERAPEUTICS INC-A?

The financial health rating of CARDIOL THERAPEUTICS INC-A (CRDL.CA) is 4 / 10.


What is the earnings growth outlook for CARDIOL THERAPEUTICS INC-A?

The Earnings per Share (EPS) of CARDIOL THERAPEUTICS INC-A (CRDL.CA) is expected to grow by 27% in the next year.